CD8A and hepatocellular carcinoma: VISTA is a novel negative checkpoint regulator, but its expression is substantially related to CD8+ TILs; hence dual positive VISTA+/CD8+ revealed a favorable TME, resulting in a better OS than VISTA-negative expression in 183 HCC tissue microarray [83, 84].